Bicara Therapeutics, Inc. (BCAX)
22.02
-0.62
(-2.74%)
USD |
NASDAQ |
Sep 21, 16:00
22.02
0.00 (0.00%)
After-Hours: 20:00
Bicara Therapeutics Enterprise Value : 996.58M for Sept. 18, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 18, 2026 | 996.58M |
| September 17, 2026 | 993.29M |
| September 16, 2026 | 954.39M |
| September 15, 2026 | 998.56M |
| September 14, 2026 | 1.034B |
| September 11, 2026 | 1.008B |
| September 10, 2026 | 1.027B |
| September 09, 2026 | 1.063B |
| September 08, 2026 | 1.067B |
| September 04, 2026 | 1.032B |
| September 03, 2026 | 1.043B |
| September 02, 2026 | 1.057B |
| September 01, 2026 | 1.048B |
| August 31, 2026 | 1.028B |
| August 28, 2026 | 1.049B |
| August 27, 2026 | 1.141B |
| August 26, 2026 | 1.134B |
| August 25, 2026 | 1.124B |
| August 24, 2026 | 1.059B |
| August 21, 2026 | 1.080B |
| August 20, 2026 | 1.112B |
| August 19, 2026 | 1.209B |
| August 18, 2026 | 1.147B |
| August 17, 2026 | 1.148B |
| August 14, 2026 | 1.105B |
| Date | Value |
|---|---|
| August 13, 2026 | 1.062B |
| August 12, 2026 | 1.128B |
| August 11, 2026 | 1.070B |
| August 10, 2026 | 1.332B |
| August 07, 2026 | 1.354B |
| August 06, 2026 | 1.318B |
| August 05, 2026 | 1.211B |
| August 04, 2026 | 1.225B |
| August 03, 2026 | 1.201B |
| July 31, 2026 | 1.291B |
| July 30, 2026 | 1.236B |
| July 29, 2026 | 1.211B |
| July 28, 2026 | 1.276B |
| July 27, 2026 | 1.337B |
| July 24, 2026 | 1.285B |
| July 23, 2026 | 1.332B |
| July 22, 2026 | 1.347B |
| July 21, 2026 | 1.360B |
| July 20, 2026 | 1.294B |
| July 17, 2026 | 1.334B |
| July 16, 2026 | 1.324B |
| July 15, 2026 | 1.358B |
| July 14, 2026 | 1.357B |
| July 13, 2026 | 1.360B |
| July 10, 2026 | 1.410B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 9.157B |
| Oncolytics Biotech, Inc. | 92.30M |
| Sangamo Therapeutics, Inc. | 51.77M |
| Sarepta Therapeutics, Inc. | 2.381B |
| Anixa Biosciences, Inc. | 80.84M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -55.44M |
| Total Expenses (Quarterly) | 55.44M |
| EPS Diluted (Quarterly) | -0.8161 |
| Earnings Yield | -14.01% |
| Normalized Earnings Yield | -14.01 |